NZ630908A - Heterocyclic compounds and methods of their use - Google Patents
Heterocyclic compounds and methods of their useInfo
- Publication number
- NZ630908A NZ630908A NZ630908A NZ63090814A NZ630908A NZ 630908 A NZ630908 A NZ 630908A NZ 630908 A NZ630908 A NZ 630908A NZ 63090814 A NZ63090814 A NZ 63090814A NZ 630908 A NZ630908 A NZ 630908A
- Authority
- NZ
- New Zealand
- Prior art keywords
- receptor
- methods
- compounds
- heterocyclic compounds
- antagonizing
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 101150116411 AGTR2 gene Proteins 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- 101800000733 Angiotensin-2 Proteins 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- 229950006323 angiotensin ii Drugs 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013902513A AU2013902513A0 (en) | 2013-07-08 | Method of treatment or prophylaxis | |
| PCT/AU2014/050116 WO2015003223A1 (en) | 2013-07-08 | 2014-07-08 | Heterocyclic compounds and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ630908A true NZ630908A (en) | 2017-08-25 |
Family
ID=52279233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ630908A NZ630908A (en) | 2013-07-08 | 2014-07-08 | Heterocyclic compounds and methods of their use |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9714224B2 (https=) |
| EP (1) | EP3019477B1 (https=) |
| JP (1) | JP6505682B2 (https=) |
| CN (1) | CN105358532B (https=) |
| ES (1) | ES2883155T3 (https=) |
| NZ (1) | NZ630908A (https=) |
| PL (1) | PL3019477T3 (https=) |
| PT (1) | PT3019477T (https=) |
| WO (1) | WO2015003223A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013202982C1 (en) | 2012-01-06 | 2017-01-05 | Novartis Ag | Heterocyclic compounds and methods for their use |
| PL3268356T3 (pl) * | 2015-03-12 | 2022-01-24 | Novartis Ag | Związki heterocykliczne i sposoby ich stosowania |
| CN106478502B (zh) * | 2015-08-29 | 2021-04-27 | 上海翰森生物医药科技有限公司 | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 |
| WO2018224037A1 (zh) * | 2017-06-09 | 2018-12-13 | 南京明德新药研发股份有限公司 | 作为at2r受体拮抗剂的羧酸衍生物 |
| US11485725B2 (en) | 2017-12-15 | 2022-11-01 | Auransa Inc. | Derivatives of piperlongumine and uses thereof |
| CN112313222B (zh) * | 2018-06-19 | 2024-01-26 | 浙江海正药业股份有限公司 | 四氢异喹啉类衍生物、其制备方法及其用途 |
| WO2020012266A1 (en) * | 2018-07-12 | 2020-01-16 | Novartis Ag | Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase |
| US12559449B2 (en) | 2019-05-10 | 2026-02-24 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Aromatic ring or heteroaromatic ring derivatives, preparation method therefor and use thereof |
| CN111620816B (zh) * | 2020-05-27 | 2023-06-02 | 上海赛默罗生物科技有限公司 | 螺桨烷类衍生物、其制备方法、药物组合物和用途 |
| CN113880825B (zh) | 2020-07-01 | 2025-03-14 | 浙江海正药业股份有限公司 | 四氢异喹啉类衍生物的盐、其制备方法及其医药应用 |
| CN111777555B (zh) * | 2020-09-04 | 2020-12-01 | 上海赛默罗生物科技有限公司 | 脂肪环烷衍生物、其制备方法、药物组合物和其应用 |
| WO2023006893A1 (en) | 2021-07-30 | 2023-02-02 | Confo Therapeutics N.V. | Compounds for the treatment of pain, in particular neuropathic pain, and/or other diseases or disorders that are associated with at2r and/or at2r mediated signaling |
| CN117603088A (zh) * | 2023-10-28 | 2024-02-27 | 广东工业大学 | 一种基于氨基酸乙酯的芳香醛席夫碱及其在不对称烷基化中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55127373A (en) * | 1979-03-26 | 1980-10-02 | Takeda Chem Ind Ltd | Tetrahydroisoquinoline compound and its preparation |
| US5246943A (en) * | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| AU2002357692A1 (en) * | 2001-11-09 | 2003-05-26 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity |
| WO2006055951A2 (en) * | 2004-11-19 | 2006-05-26 | Portola Pharmaceuticals, Inc. | Tetrahydroisoquinolines as factor xa inhibitors |
| PT1830869E (pt) | 2004-12-24 | 2013-08-22 | Spinifex Pharm Pty Ltd | Método de tratamento ou profilaxia |
| CA2646379C (en) * | 2006-03-20 | 2014-12-23 | The University Of Queensland | Method of treatment or prophylaxis inflammatory pain |
| US9095587B2 (en) * | 2010-01-19 | 2015-08-04 | Spinifex Pharmaceuticals Pty Ltd | Methods and compositions for improved nerve conduction velocity |
| ES2570135T3 (es) * | 2010-07-21 | 2016-05-17 | Novartis Ag | Sal y solvatos de un derivado de tetrahidroisoquinolina |
| AU2013202982C1 (en) | 2012-01-06 | 2017-01-05 | Novartis Ag | Heterocyclic compounds and methods for their use |
| PL2807153T3 (pl) | 2012-01-25 | 2020-09-07 | Novartis Ag | Związki heterocykliczne i sposoby ich zastosowania |
| PT2807171T (pt) | 2012-01-25 | 2020-11-03 | Novartis Ag | Compostos heterocíclicos e métodos para a sua utilização |
-
2014
- 2014-07-08 NZ NZ630908A patent/NZ630908A/en unknown
- 2014-07-08 PL PL14823688T patent/PL3019477T3/pl unknown
- 2014-07-08 EP EP14823688.8A patent/EP3019477B1/en active Active
- 2014-07-08 ES ES14823688T patent/ES2883155T3/es active Active
- 2014-07-08 US US14/903,166 patent/US9714224B2/en active Active
- 2014-07-08 CN CN201480038866.XA patent/CN105358532B/zh active Active
- 2014-07-08 PT PT148236888T patent/PT3019477T/pt unknown
- 2014-07-08 WO PCT/AU2014/050116 patent/WO2015003223A1/en not_active Ceased
- 2014-07-08 JP JP2016524633A patent/JP6505682B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016525093A (ja) | 2016-08-22 |
| US20160145213A1 (en) | 2016-05-26 |
| EP3019477A4 (en) | 2017-01-11 |
| CN105358532A (zh) | 2016-02-24 |
| PL3019477T3 (pl) | 2021-11-22 |
| EP3019477B1 (en) | 2021-05-26 |
| CN105358532B (zh) | 2019-07-23 |
| PT3019477T (pt) | 2021-08-20 |
| WO2015003223A1 (en) | 2015-01-15 |
| JP6505682B2 (ja) | 2019-04-24 |
| ES2883155T3 (es) | 2021-12-07 |
| EP3019477A1 (en) | 2016-05-18 |
| US9714224B2 (en) | 2017-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ630908A (en) | Heterocyclic compounds and methods of their use | |
| PH12020550622A1 (en) | Kras g12c inhibitors | |
| PH12017501481A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| AU2019268062A1 (en) | Benzoquinolone inhibitors of VMAT2 | |
| SG10201902326XA (en) | Mk2 inhibitors and uses thereof | |
| PH12015502621A1 (en) | Estrogen receptor modulator and uses thereof | |
| PH12016500739A1 (en) | Inhibitors of the fibrolast growth factor receptor | |
| MX2015008999A (es) | Inhibidores mk2 y usos de los mismos. | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| MY199711A (en) | Bicyclic heterocycles as fgfr inhibitors | |
| PH12015502041B1 (en) | Heteroaryl compounds and uses thereof | |
| SG10201810879VA (en) | Pharmaceutical compounds | |
| MY192489A (en) | Selectively substituted quinoline compounds | |
| MY191581A (en) | Anti-pd-1 antibodies | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| EP3450449A3 (en) | Peptide compositions | |
| WO2015120138A3 (en) | AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF | |
| MX2016004540A (es) | Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda). | |
| PH12017500348B1 (en) | Tetrahydroquinoline derivatives as bromodomain inhibitors | |
| SA516370737B1 (ar) | Cgrp صيغ لمضادات مستقبل | |
| TW201613934A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| WO2016109361A3 (en) | 3-fluoro-benzonitrile inhibitors of 11-beta-hydroxylase | |
| MX371343B (es) | Moduladores del receptor x hepatico (lxr). | |
| MX2016002930A (es) | Moduladores del receptor x hepatico (lxr). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: NOVARTIS AG, CH Effective date: 20160107 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2019 BY CPA GLOBAL Effective date: 20180622 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2020 BY CPA GLOBAL Effective date: 20190620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2021 BY CPA GLOBAL Effective date: 20200618 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2022 BY CPA GLOBAL Effective date: 20210617 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2023 BY CPA GLOBAL Effective date: 20220616 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2024 BY CPA GLOBAL Effective date: 20230622 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 JUL 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240620 |